SAD Study to Evaluate Safety, Tolerability, and Pharmacokinetic Profile of KSHN001126 in Healthy Post-Menopausal Females
NCT ID: NCT06467201
Last Updated: 2024-07-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
PHASE1
18 participants
INTERVENTIONAL
2024-06-30
2025-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SEQUENTIAL
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
KSHN001126 150mg
Low Dose
KSHN001126 150mg
6 subjects will receive single oral dose of 150mg
KSHN001126 300mg
Mid Dose
KSHN001126 300mg
6 subjects will receive single oral dose of 300mg
KSHN001126 600mg
High Dose
KSHN001126 600mg
6 subjects will receive single oral dose of 600mg
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
KSHN001126 150mg
6 subjects will receive single oral dose of 150mg
KSHN001126 300mg
6 subjects will receive single oral dose of 300mg
KSHN001126 600mg
6 subjects will receive single oral dose of 600mg
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Healthy, postmenopausal females aged 45 to 60 years old (inclusive), as determined by medical history and physical examination.
3. Body Mass Index at screening between 18 and 30 kg/m2, inclusive.
4. Post-menopausal females (Menopause is defined as the female is either 12 months off menstrual period after the age of 50 years, or 12 months off menstrual period after the age of 40 years and Follicle Stimulating Hormone (FSH) \> 40 mIU/mL. Amenorrhea should not be due to lactation).
5. In good general health with no clinically significant illness seen on physical examination or ongoing medical history, as determined by the Investigator.
6. Documented 12-lead ECG with no clinically significant abnormalities (with QTc interval between 360 to 440 msec), as determined by the Investigator in screening or Day 0.
7. No clinically significant abnormalities in screening or Day 0 laboratory tests, as determined by the Investigator (Creatinine clearance should be ≥ 90 mL/min and Blood Urea Nitrogen / AST / ALT / Alkaline phosphatase / Total and direct bilirubin should be \< upper limit of normal).
8. Female participants must have a negative serum pregnancy (β-HCG) test at screening and a negative urine pregnancy test at Day 0 prior to dosing. Female participants must also be non-lactating.
9. The participant is available to volunteer for the entire study duration and is willing to adhere to all protocol requirements.
10. The participant has vital signs at screening, and at check-in within the following ranges:
* Blood Pressure:
* Systolic: (100- 140 mmHg
* Diastolic: (60-90) mmHg
* Body Temperature: (36.1 - 37.8) ºC, Pulse rate: 60 to 100 b/m. Respiratory rate: 12 to 20 bpm
11. Participants with normal findings as determined by gynecological examination and USG Pelvis.
12. With a normal or clinically acceptable mammogram
13. With a normal or clinically acceptable PAP smear test
14. Have a normal chest X-ray (P. A. view).
15. Participant negative for hepatitis B-surface antigen, hepatitis C and Human Immunodeficiency Virus (HIV)
16. Participants who are generally healthy as determined by medical evaluation, including medical history, physical examination, laboratory tests, and cardiac monitoring
17. Adequate venous access and can able to give required blood samples.
Exclusion Criteria
2. Pregnant or lactating female participant.
3. Any history of clinically significant cardiac, renal, neurologic, metabolic, pulmonary, gastrointestinal, chronic hepatic disease or any other disease which in the judgment of the Investigator would interfere with the study or confound the study results.
4. History of allergy or major allergic reaction considered to be clinically significant by the Investigator.
5. Receiving or has received any investigational drug within the 30 days before receiving KSHN001126.
6. History or presence of low platelet count, bleeding issues or family history of bleeding disorders.
7. Participant has a history of hypersensitivity to heparin as checked at screening.
8. The participant has known allergy to the drug under investigation, or to any ingredient in the preparation
9. The participant has an evidence of antagonistic personality, poor motivation, emotional or intellectual problems likely to limit the validity of the consent to participation in the study or limit the ability to comply with the protocol requirements.
10. Donated blood within 60 days of screening or otherwise experienced blood loss of \>250 mL within the same period.
11. Intending to begin new concomitant drug therapy or over-the-counter medication anytime from screening to the time of administration of study drug.
12. Received or intending to receive a vaccination in the two weeks prior to dosing, or anytime during study participation.
13. Received treatment with a drug that has not received regulatory approval for an indication during the 60 days preceding study enrollment.
14. History of drug and/or alcohol dependence within past 12 months, and/or positive results on drug of abuse or alcohol tests.
15. The participant is a smoker (smoker is defined as reporting tobacco use in the previous 3 months and/or has urine cotinine level equal or more than 500 ng/ml)
16. Has taken any regular, prescribed, or over-the-counter medication with the exception of acetaminophen (maximum 2 g/day) or multi- vitamins in the 2 weeks prior to dosing (other medication may only be taken with the specific approval of the Investigator in consultation with the Medical Monitor).
17. The participant with history of consuming alcohol or caffeine or related xanthine containing foods or beverages such as caffeine in tea, coffee, chocolates, cola and pepsi for 48 hours prior to dosing.
18. The participant has consumed grapefruit-containing beverages and foods 7 days prior to dosing.
19. Malignancy within the last 5 years, with the exception of successfully treated basal cell carcinoma and carcinoma in situ uteri.
20. The participant has prior history of hormonal replacement therapy.
21. The participant has any estrogen- dependent conditions including breast cancer.
22. Any condition that, in the opinion of the investigator, might interfere with study objectives.
23. The participant has a history of osteoporosis or any disease affecting bone or steroid metabolism.
24. Intolerance to/ fear of venipuncture, needles, or blood draws
45 Years
60 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Eric Solutions LLC
UNKNOWN
Clinexcel Research, Ahmedabad, India
UNKNOWN
Shivanka Research, LLC
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Advanced Pharma CR
Miami, Florida, United States
Health1 Superspeciality Hospital
Ahmedabad, Gujarat, India
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Sachin Bidani
Role: primary
Jayesh Sanmukhani
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CE-24-02
Identifier Type: -
Identifier Source: org_study_id